VILTEPSO: An FDA-Approved Duchenne Treatment for Patients Amenable to Exon 53 Skipping

When:
March 30, 2023 4:00PM

Join Jett Foundation’s Community Webinar Series on March 30 at 4PM ET as we welcome NS Pharma for a presentation and discussion on VILTEPSO, an FDA-approved treatment for Duchenne for patients amenable to exon 53 skipping.

VILTEPSO: An FDA-Approved Duchenne Treatment for Patients Amenable to Exon 53 Skipping
Thursday, March 30, 2023
4PM ET | 3PM CT | 2PM MT | 1PM PT

 

Chamindra Laverty Konersman, MD

Guest Speaker

Chamindra Laverty (Konersman), MD, is a board-certified neurologist and neuromuscular specialist at UC San Diego Health, Rady Children’s Hospital and San Diego VA Health Systems. She provides speciality neuromuscular care to people with a range of neurologic conditions including hereditary motor neuron disease, inclusion body myositis, Guillain-Barré syndrome, myasthenia gravis, Charcot-Marie-Tooth disease, periodic paralysis, and all muscular dystrophies. She also participates in a wide range of clinical trials serving pediatric and adult patients. 

Community Webinar Series - Better preparing for challenges in Duchenne

Our Community Webinar Series is focused on ensuring that our Duchenne community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.

No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.

Experience the magic this summer!

How is the rare disease community accomplishing goals?

Tune in on February 29 to hear from our panel and moderators on how they are accomplishing goals and living life to the fullest!

Your gift helps Jett Foundation provide programming and opportunities, such as Camp Promise, to many families impacted by Duchenne muscular dystrophy each year.

Accessible Vehicle Fund Applications Open